Stem cell transplant from matched or partially matched donors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies stem cell transplants from donors that are fully or partially matched to patients with blood cancers. It compares a new stem cell product from Ossium Health with standard donor transplants to see how well they work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 75 years old, depending on the type of transplant you receive.
- You must have a blood cancer like leukemia, lymphoma, MDS, CLL, or CML that has not spread to the brain.
- You must need your first stem cell transplant from a donor.
- You must have a donor that is at least a partial HLA match (4 to 8 out of 8 markers).
- You must be in fairly good health, with a performance score of 60% or higher and no major organ problems.
- You cannot have had a prior stem cell transplant or certain other treatments like CAR-T therapy within the last few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.